Optum
Summary New Core Watchlist Market Weak signals Manual checks Gaps & log Sources
Executive summary
- Optum's life-sciences RWD sits in Optum Insight as 'Optum Life Sciences' (the ex-HEOR group, now 'Value & Evidence Solutions') plus OptumLabs for research collaborations — a clean structural analog to Inovalon's Insights/RWD BU but at far greater scale. ↳
- Optum is NOT thin on EHR the way Inovalon is: Market Clarity is a genuine curated EHR+claims asset (~70M lives, labs/vitals/NLP-extracted notes, 20K+ clinical variables from 50+ health systems) — this contradicts the 'Optum is just claims' hypothesis and is a capability Inovalon lacks. ↳
- BUT Optum's regulatory-grade RWE is still claims-first in practice: its claims asset Clinformatics is named in 5 pharma pharmacoepi/safety trials (Janssen x3, Novartis, Bayer) while the EHR asset Market Clarity appears in zero — so on the workhorse-asset axis Optum looks like Inovalon, just bigger. ↳
- The 'neutral data partner' wedge is positionable but UNPROVEN: no documented case surfaced of pharma avoiding Optum RWD over UHG conflict-of-interest; the heavy, current UHG conflict scrutiny is all in insurance/PBM/provider/cyber domains, not pharma data buying. ↳
- Optum/UHG carries severe, current (2026) regulatory and reputational overhang — including the Change Healthcare breach (largest US healthcare breach ever, ~192.7M people, no global settlement as of Feb 2026) — but it sits on the corporate parent, not the RWD product line. ↳
- Optum is mid-crisis at the top: Witty out as UHG CEO (May 2025), Hemsley back, Dr. Patrick Conway installed as Optum CEO (May 1, 2025), CFO replaced, 2025 guidance suspended — leadership turmoil that plausibly distracts from the pharma-RWD roadmap. ↳
- Optum's marquee 2025 AI investment (Optum Real + Microsoft, Suki) targets provider/payer claims-and-reimbursement workflow — NOT life-sciences RWD — suggesting the pharma-RWD product is not where the innovation energy is going. ↳
- Optum is a top-tier RWE vendor (2025 Frost & Sullivan RWE leader; FDA Sentinel network partner) but IQVIA remains the high-end scale leader, and Optum discloses no top-20-pharma penetration metrics. ↳
New since last run
factnew Optum's life-sciences RWD business is organized inside the Optum Insight segment as 'Optum Life Sciences' (the former HEOR group, rebranded 'Value & Evidence Solutions', led by VP Stacey DaCosta Byfield) for commercial data licensing/HEOR/epidemiology, with OptumLabs serving as the academic/pharma research-collaboration arm — Optum's three operating divisions remain Optum Health, Optum Insight, and Optum Rx.
factnew Optum's anchor licensable RWD asset, the de-identified Clinformatics Data Mart, is a 100% closed administrative-claims system of commercial and Medicare Advantage members covering roughly 67 million people across all 50 states from 2007 onward, with medical/pharmacy/inpatient claims plus lab results — i.e. primarily a CLAIMS asset (company/aggregator figures; the ~67M is a long-standing figure and some sources cite ~126M cumulative since 2007, so vintage should be flagged).
factnew Optum DOES hold a curated research-grade EHR asset: Market Clarity links de-identified EHR with multi-payer claims for 70M+ patient lives, with clinically rich elements (lab results, vital signs, diagnoses, procedures, and information extracted from unstructured clinical notes via NLP), spanning 20,000+ mapped clinical variables and EHR contributed from 50+ large US health systems — a depth Inovalon's claims-first stack lacks.
factnew The OptumLabs Data Warehouse (OLDW) — the research backbone behind OptumLabs collaborations — holds de-identified longitudinal medical+pharmacy claims, lab results and enrollment for 200M+ commercial and Medicare Advantage enrollees across all 50 states plus DC, with linked EHR for a subset; it is independently described (UCSF, U-Maryland) as one of the largest linked claims+EHR databases in the US.
inferencenew Optum's regulatory-grade RWE footprint is claims-first in practice: ClinicalTrials.gov records name the claims asset 'Optum Clinformatics' as the data source in 5 pharma pharmacoepidemiology/drug-safety studies (Janssen on canagliflozin, fluoroquinolones, and methotrexate-vs-anti-TNF dementia; Novartis ofatumumab real-world effectiveness; Bayer post-ICU ARDS), while the EHR asset 'Optum Market Clarity' is named in zero — so the workhorse asset is claims, mirroring Inovalon.
factnew Optum is one of ~18 partner institutions in the FDA Sentinel System distributed data network (alongside Aetna, BCBS Massachusetts, Duke, Kaiser Permanente, HCA), giving its claims data a regulatory-grade active-safety-surveillance credential — a bar Inovalon's clinical-RWD build would need to clear to compete for the same regulatory use cases.
inferencenew 2025-2026 peer-reviewed RWE built on Optum data is dominantly claims-based economic-burden and safety work in commercial + Medicare Advantage populations (e.g., idiopathic/progressive pulmonary fibrosis burden, light-chain amyloidosis), with explicit claims-linked-EHR analyses a clear minority — corroborating that Optum's published research center-of-gravity is claims, not EHR.
factnew Optum Insight (the segment housing the RWD business) reported FY2025 revenue of $19.4B, up 4% (+$660M) YoY, but operating earnings FELL to $2.6B from $3.1B in 2024 — margin compression consistent with the Change Healthcare cyberattack aftermath; the Life Sciences/RWD line is not separately disclosed, so segment revenue overstates the addressable RWD competitor (figures as originally reported, before the Jan-2026 realignment that folded Optum Financial into Optum Insight and recast prior periods).
inferencenew The 'neutral data partner' wedge against Optum is positionable but unproven: no documented case surfaced of pharma/life-sciences buyers declining Optum RWD over UHG channel-conflict or competitive-intelligence fears; the heavily documented UHG conflicts of interest are in insurance, PBM, and provider-self-dealing domains (e.g., the DOJ's 2022 Change Healthcare suit argued the deal would expose rival INSURERS' data; StatNews documented Optum paying its own physician groups more) — adjacent reputational air-cover for a neutrality message, not evidence pharma actually avoids Optum data.
factnew A DOJ antitrust investigation into UnitedHealth Group/Optum is active as of 2026 — examining whether Optum's ownership of physician groups disadvantages rival insurers and whether UHG favors Optum-owned providers in contracting, plus OptumRx billing and physician reimbursement — with no charges filed yet; DOJ is separately reviewing UHG's $3.3B Amedisys home-health acquisition.
factnew UnitedHealth confirmed it is complying with BOTH civil and criminal DOJ requests in a probe of its Medicare Advantage risk-adjustment/diagnosis-coding practices (whether diagnoses were inflated to trigger overpayments); UHG points to favorable CMS audits and a prior Special Master finding of no wrongdoing, but the DOJ's January 14, 2026 record-setting Kaiser MA risk-adjustment settlement signals intensifying sector scrutiny — directly relevant context for an Inovalon RADV/risk-adjustment posture.
factnew The February 2024 ransomware attack on Change Healthcare (part of Optum Insight) remains the largest healthcare data breach in US history at ~192.7M people affected; as of February 2026 no final global settlement has been approved (78+ consolidated class actions in D. Minnesota MDL), after UHG booked ~$1.6B+ in direct 2024 costs and advanced $9B+ in provider loans — a data-stewardship liability attached to the same Optum Insight unit that sells RWD.
factnew Optum's leadership was overhauled during a 2025 crisis: Andrew Witty stepped down as UHG CEO on May 13, 2025 and Stephen Hemsley (CEO 2006-2017) returned; Dr. Patrick Conway (ex-CMS, physician) became Optum CEO effective May 1, 2025; Wayne DeVeydt became CFO in September 2025; and UHG suspended its 2025 financial guidance on higher-than-expected medical costs.
factnew Optum's flagship 2025 AI push — 'Optum Real' (real-time claims/reimbursement), unveiled at HLTH 2025 with a Microsoft partnership (Azure, Dragon Copilot, Foundry) and an AI-scribe collaboration with Suki — is aimed at provider/payer claims-and-documentation workflow, NOT life-sciences RWD, indicating the pharma-RWD product is not the locus of Optum's headline AI investment.
factnew Optum Life Sciences was named the 2025 Leader in Real-World Evidence Solutions by Frost & Sullivan and has rebranded its HEOR practice as 'Value & Evidence Solutions' — evidence the pharma-RWD unit is actively marketed and externally validated even amid the parent-company turmoil.
inferencenew Optum sits in the top tier of RWE vendors (2025 Frost & Sullivan RWE leader; named alongside IQVIA as a foremost player in third-party market maps) but IQVIA is consistently positioned as the high-end scale leader; the RWE-solutions market is sized at roughly $3B in 2025 growing ~8%/year, and Optum discloses no top-20-pharma customer-penetration metrics (a gap independent sources could not fill).
factnew Optum's stated pharma value proposition centers on claims-to-EHR linkage at scale — e.g., OptumLabs links prescription information from EHR with claims to verify whether prescriptions were actually filled — making the integrated longitudinal claims+clinical view (not raw EHR depth alone) its core differentiator and the specific capability an Inovalon clinical-RWD build must match.
Core competitors
Watchlist headlines
Optum
factnew Optum's life-sciences RWD business is organized inside the Optum Insight segment as 'Optum Life Sciences' (the former HEOR group, rebranded 'Value & Evidence Solutions', led by VP Stacey DaCosta Byfield) for commercial data licensing/HEOR/epidemiology, with OptumLabs serving as the academic/pharma research-collaboration arm — Optum's three operating divisions remain Optum Health, Optum Insight, and Optum Rx.
factnew Optum's anchor licensable RWD asset, the de-identified Clinformatics Data Mart, is a 100% closed administrative-claims system of commercial and Medicare Advantage members covering roughly 67 million people across all 50 states from 2007 onward, with medical/pharmacy/inpatient claims plus lab results — i.e. primarily a CLAIMS asset (company/aggregator figures; the ~67M is a long-standing figure and some sources cite ~126M cumulative since 2007, so vintage should be flagged).
factnew Optum DOES hold a curated research-grade EHR asset: Market Clarity links de-identified EHR with multi-payer claims for 70M+ patient lives, with clinically rich elements (lab results, vital signs, diagnoses, procedures, and information extracted from unstructured clinical notes via NLP), spanning 20,000+ mapped clinical variables and EHR contributed from 50+ large US health systems — a depth Inovalon's claims-first stack lacks.
factnew The OptumLabs Data Warehouse (OLDW) — the research backbone behind OptumLabs collaborations — holds de-identified longitudinal medical+pharmacy claims, lab results and enrollment for 200M+ commercial and Medicare Advantage enrollees across all 50 states plus DC, with linked EHR for a subset; it is independently described (UCSF, U-Maryland) as one of the largest linked claims+EHR databases in the US.
inferencenew Optum's regulatory-grade RWE footprint is claims-first in practice: ClinicalTrials.gov records name the claims asset 'Optum Clinformatics' as the data source in 5 pharma pharmacoepidemiology/drug-safety studies (Janssen on canagliflozin, fluoroquinolones, and methotrexate-vs-anti-TNF dementia; Novartis ofatumumab real-world effectiveness; Bayer post-ICU ARDS), while the EHR asset 'Optum Market Clarity' is named in zero — so the workhorse asset is claims, mirroring Inovalon.
factnew Optum is one of ~18 partner institutions in the FDA Sentinel System distributed data network (alongside Aetna, BCBS Massachusetts, Duke, Kaiser Permanente, HCA), giving its claims data a regulatory-grade active-safety-surveillance credential — a bar Inovalon's clinical-RWD build would need to clear to compete for the same regulatory use cases.
inferencenew 2025-2026 peer-reviewed RWE built on Optum data is dominantly claims-based economic-burden and safety work in commercial + Medicare Advantage populations (e.g., idiopathic/progressive pulmonary fibrosis burden, light-chain amyloidosis), with explicit claims-linked-EHR analyses a clear minority — corroborating that Optum's published research center-of-gravity is claims, not EHR.
factnew Optum Insight (the segment housing the RWD business) reported FY2025 revenue of $19.4B, up 4% (+$660M) YoY, but operating earnings FELL to $2.6B from $3.1B in 2024 — margin compression consistent with the Change Healthcare cyberattack aftermath; the Life Sciences/RWD line is not separately disclosed, so segment revenue overstates the addressable RWD competitor (figures as originally reported, before the Jan-2026 realignment that folded Optum Financial into Optum Insight and recast prior periods).
inferencenew The 'neutral data partner' wedge against Optum is positionable but unproven: no documented case surfaced of pharma/life-sciences buyers declining Optum RWD over UHG channel-conflict or competitive-intelligence fears; the heavily documented UHG conflicts of interest are in insurance, PBM, and provider-self-dealing domains (e.g., the DOJ's 2022 Change Healthcare suit argued the deal would expose rival INSURERS' data; StatNews documented Optum paying its own physician groups more) — adjacent reputational air-cover for a neutrality message, not evidence pharma actually avoids Optum data.
factnew A DOJ antitrust investigation into UnitedHealth Group/Optum is active as of 2026 — examining whether Optum's ownership of physician groups disadvantages rival insurers and whether UHG favors Optum-owned providers in contracting, plus OptumRx billing and physician reimbursement — with no charges filed yet; DOJ is separately reviewing UHG's $3.3B Amedisys home-health acquisition.
factnew UnitedHealth confirmed it is complying with BOTH civil and criminal DOJ requests in a probe of its Medicare Advantage risk-adjustment/diagnosis-coding practices (whether diagnoses were inflated to trigger overpayments); UHG points to favorable CMS audits and a prior Special Master finding of no wrongdoing, but the DOJ's January 14, 2026 record-setting Kaiser MA risk-adjustment settlement signals intensifying sector scrutiny — directly relevant context for an Inovalon RADV/risk-adjustment posture.
factnew The February 2024 ransomware attack on Change Healthcare (part of Optum Insight) remains the largest healthcare data breach in US history at ~192.7M people affected; as of February 2026 no final global settlement has been approved (78+ consolidated class actions in D. Minnesota MDL), after UHG booked ~$1.6B+ in direct 2024 costs and advanced $9B+ in provider loans — a data-stewardship liability attached to the same Optum Insight unit that sells RWD.
factnew Optum's leadership was overhauled during a 2025 crisis: Andrew Witty stepped down as UHG CEO on May 13, 2025 and Stephen Hemsley (CEO 2006-2017) returned; Dr. Patrick Conway (ex-CMS, physician) became Optum CEO effective May 1, 2025; Wayne DeVeydt became CFO in September 2025; and UHG suspended its 2025 financial guidance on higher-than-expected medical costs.
factnew Optum's flagship 2025 AI push — 'Optum Real' (real-time claims/reimbursement), unveiled at HLTH 2025 with a Microsoft partnership (Azure, Dragon Copilot, Foundry) and an AI-scribe collaboration with Suki — is aimed at provider/payer claims-and-documentation workflow, NOT life-sciences RWD, indicating the pharma-RWD product is not the locus of Optum's headline AI investment.
factnew Optum Life Sciences was named the 2025 Leader in Real-World Evidence Solutions by Frost & Sullivan and has rebranded its HEOR practice as 'Value & Evidence Solutions' — evidence the pharma-RWD unit is actively marketed and externally validated even amid the parent-company turmoil.
inferencenew Optum sits in the top tier of RWE vendors (2025 Frost & Sullivan RWE leader; named alongside IQVIA as a foremost player in third-party market maps) but IQVIA is consistently positioned as the high-end scale leader; the RWE-solutions market is sized at roughly $3B in 2025 growing ~8%/year, and Optum discloses no top-20-pharma customer-penetration metrics (a gap independent sources could not fill).
factnew Optum's stated pharma value proposition centers on claims-to-EHR linkage at scale — e.g., OptumLabs links prescription information from EHR with claims to verify whether prescriptions were actually filled — making the integrated longitudinal claims+clinical view (not raw EHR depth alone) its core differentiator and the specific capability an Inovalon clinical-RWD build must match.
Market & demand signals
No demand-side findings this run.
Weak signals
Single-signal inferences — interpret with caution.
inferenceweak signalnew OptumLabs temporarily paused contracting NEW academic research partners from fall 2025 through spring 2026 (projects under existing master license agreements continue) — a pause in the research-collaboration arm that coincides with the UHG leadership/financial turmoil and could signal a window where Optum's RWD research outreach is muted.
inferenceweak signalnew Optum Life Sciences / OptumLabs show active hiring in real-world evidence, HEOR, epidemiology and commercial analytics on third-party job boards as of mid-2026, indicating the pharma-RWD BU is staffed and operating (not wound down); absolute counts are unreliable because Optum has no clean public ATS — careers run on Radancy — and aggregator totals conflate the whole company.
Manual checks
Search LinkedIn for posts since May 2025 by Dr. Patrick Conway (Optum CEO) and by Stacey DaCosta Byfield (VP, Value & Evidence Solutions) for life-sciences RWD roadmap signals the scripted sources can't see. — https://www.linkedin.com/search/results/content/?keywords=Optum%20Life%20Sciences%20real-world%20evidence
Check KLAS and Gartner (paywalled) for Optum Life Sciences / Clinformatics / Market Clarity vendor ratings vs IQVIA, Aetion, Komodo to triangulate the competitive-standing and top-20-pharma-penetration gap left open here. — https://klasresearch.com/
Manually browse Optum's careers site for open 'Life Sciences' / 'real-world evidence' / 'epidemiology' / 'HEOR' requisitions to gauge whether the pharma-RWD BU is investing or contracting — the only reliable hiring read since there is no scrapeable ATS. — https://careers.unitedhealthgroup.com/
Confirm whether OptumLabs resumed contracting new academic research partners after the stated spring-2026 pause window; resumption (or extension) is itself a signal about OptumLabs' health post-UHG-turmoil. — https://labs.optum.com/
Open question worth a direct vendor/RFI check: how much of Market Clarity's EHR comes from Optum Health/OptumCare owned physician groups vs the 50+ contributed external health systems — material to whether Optum has a unique owned-clinic data moat or a contributor network like Truveta/Veradigm. — https://business.optum.com/en/data-analytics/life-sciences/real-world-data/market-clarity-data.html
Coverage gaps & run log
Coverage gaps
| Company | Category | Reason |
|---|---|---|
| Optum | regulatory | all 2 scripted attempt(s) empty/failed (cap 4 for core tier) |
| Optum | jobs | No public/scrapeable ATS (Radancy JSON-wrapping-HTML); web-search fallback only — absolute hiring counts unreliable. |
| Optum | regulatory | openFDA 510k/PMA = 0 (expected: Optum is a data vendor, not a device applicant); regulatory signal came from web search (FDA Sentinel, DOJ probes). |
| Optum | financial | Optum Life Sciences / RWD revenue not separately disclosed — only the full Optum Insight segment ($19.4B FY2025) is reported; true RWD-competitor revenue is unknowable from filings. |
| Optum | market_demand | Tier-3 demand-side (USAspending) intentionally skipped (no --all-sources on this deep dive). |
| Optum | regulatory | No API keys for regulations.gov / SAM.gov / USPTO (TSDR) — docket-comment, contract-opportunity, and trademark-status sources skipped. |
| Optum | product | TRUST/channel-conflict thesis: found NO direct documented evidence pharma avoids Optum RWD over UHG ownership — wedge is positionable, not demand-proven (decision-relevant null result). |
| Optum | product | Market Clarity EHR provenance: split between OptumCare-owned physician groups vs 50+ contributed external systems not disclosed — open question for owned-data-moat assessment. |
Query log
| Source | Query | Results | Status |
|---|---|---|---|
| clinicaltrials | ct sponsor=Optum | 3 | ok |
| clinicaltrials | ct term=Optum Clinformatics | 5 | ok |
| clinicaltrials | ct term=Optum Market Clarity | 0 | ok |
| openfda-510k | 510k applicant=Optum | 0 | ok |
| openfda-pma | pma applicant=Optum | 0 | ok |
| pubmed | pubmed Optum | 231 | ok |
| nih_reporter | reporter text=Optum | 161 | ok |
| edgar-filings | edgar filings Optum | 25 | ok |
| edgar-fts | edgar fts Optum | 1905 | ok |
| pages | pages Optum | 1 | ok |
| websearch | org structure: Optum Life Sciences / Optum Insight / OptumLabs 2025-2026 | 9 | ok |
| websearch | Clinformatics Data Mart covered lives / years / data types | 9 | ok |
| websearch | Market Clarity EHR-linked claims clinical depth notes labs | 8 | ok |
| websearch | OptumLabs research collaboration pharma RWE 2025-2026 | 9 | ok |
| websearch | Optum Insight FY2025 segment revenue UnitedHealth | 5 | ok |
| websearch | pharma reluctance buying RWD from UHG-owned Optum (conflict) | 8 | empty: no documented case of pharma avoiding Optum RWD on conflict grounds |
| websearch | payer-owned vendor neutrality / pharma trust preference | 6 | ok |
| websearch | Optum Insight life sciences competitive position vs IQVIA | 5 | ok |
| websearch | UHG/Optum 'conflict of interest' insurer/PBM/provider | 8 | ok |
| websearch | Optum RWD top-20 pharma customers / market share 2025 | 9 | empty: no customer-level penetration data public |
| webfetch | IntuitionLabs 2026 RWD vendor comparison — neutrality/Inovalon | 1 | ok: report does NOT analyze payer-ownership/neutrality; no Inovalon mention (corrects batch-2 snippet) |
| websearch | DOJ antitrust investigation into UHG/Optum status 2026 | 7 | ok |
| websearch | Change Healthcare 2024 breach cost / settlement status 2026 | 7 | ok |
| websearch | DOJ Medicare Advantage risk-adjustment civil+criminal probe 2025-2026 | 8 | ok |
| websearch | UHG CEO change Witty/Hemsley + Optum CEO Patrick Conway 2025 | 8 | ok |
| websearch | Optum life-sciences RWD AI launch/partnership 2025-2026 | 8 | ok: found Optum Real+Microsoft (provider/payer claims AI, NOT life-sciences RWD) |
| webfetch | Atlas of Longitudinal Datasets — Clinformatics scale page | 0 | error: HTTP 403 Forbidden |
| websearch | Market Clarity EHR source: OptumCare-owned vs contributed systems | 8 | ok: 50+ contributed health systems; OptumCare-owned contribution not disclosed |
| websearch | OptumLabs Data Warehouse (OLDW) scale — linked claims+EHR | 10 | ok: 200M+ commercial+MA claims, EHR subset (independent: UCSF/U-Maryland) |
| websearch | Optum Life Sciences / OptumLabs hiring RWE/HEOR/epi 2025-2026 | 10 | ok: active hiring; aggregator counts unreliable (no clean ATS) |
| websearch | Optum/Clinformatics FDA Sentinel + regulatory RWE track record | 8 | ok: Optum = 1 of ~18 FDA Sentinel network partners |
Sources
Optum
- https://business.optum.com/en/data-analytics/life-sciences.html
- https://www.beckerspayer.com/payer/50-things-to-know-about-optum/
- https://ssrc.indiana.edu/news-events/_news/news-20210114-optum-public.html
- https://www.optum.com/en/business/life-sciences/real-world-data/claims-data.html
- https://business.optum.com/en/data-analytics/life-sciences/real-world-data/market-clarity-data.html
- https://www.sciencedirect.com/science/article/pii/S2214426924000545
- https://data.ucsf.edu/research/oldw
- https://www.medschool.umaryland.edu/cibr/core/optumlabs/
- https://clinicaltrials.gov/study/NCT03492580
- https://clinicaltrials.gov/study/NCT03479736
- https://clinicaltrials.gov/study/NCT06760624
- https://natlawreview.com/article/fda-expands-big-data-use-sentinel-system
- https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
- https://pubmed.ncbi.nlm.nih.gov/42254470/
- https://pubmed.ncbi.nlm.nih.gov/42110586/
- https://pubmed.ncbi.nlm.nih.gov/42189505/
- https://finance.yahoo.com/news/unitedhealth-group-reports-2025-results-105500092.html
- https://www.sec.gov/Archives/edgar/data/731766/000073176626000062/unh-20251231.htm
- https://www.healthcaredive.com/news/unitedhealth-antitrust-investigation-doj-unitedhealthcare-optum/708727/
- https://www.statnews.com/2024/11/25/unitedhealth-higher-payments-optum-providers-converts-expenses-to-profits/
- https://www.modernhealthcare.com/insurance/mh-doj-unitedhealth-optum-rx-medicare-billing/
- https://www.fiercehealthcare.com/payers/wsj-feds-investigating-unitedhealth-criminal-medicare-fraud
- https://www.mintz.com/insights-center/viewpoints/2406/2026-01-13-medicare-advantage-under-microscope-enforcement
- https://www.healthcaredive.com/news/unitedhealth-grassley-medicare-advantage-investigation/809377/
- https://www.hipaajournal.com/change-healthcare-responding-to-cyberattack/
- https://www.aboutlawsuits.com/change-healthcare-lawsuit/
- https://hospicenews.com/2025/05/13/stephen-hemsley-becomes-unitedhealth-group-ceo-as-andrew-witty-steps-down/
- https://www.startribune.com/unitedhealth-ceo-shakeup-stephen-hemsley-andrew-witty-suspends-financial-guidance/601350331
- https://stocktwits.com/news-articles/markets/equity/united-health-reshuffles-optum-execs-as-ceo-hemsley-takes-charge-of-105-b-division/chmgKYCRRIE
- https://www.healthcarefinancenews.com/news/optum-real-microsoft-partner-ai-claims-and-reimbursement
- https://www.fiercehealthcare.com/ai-and-machine-learning/optum-real-and-suki-build-out-collaboration-r1-teams-heidi-link-ai-scribe
- https://www.stocktitan.net/news/UNH/optum-applauded-by-frost-amp-sullivan-for-advancing-the-use-of-real-a9ykz4vi2tmf.html
- https://www.globenewswire.com/news-release/2025/06/19/3102076/28124/en/Life-Sciences-Real-World-Evidence-Solutions-Company-Benchmark-Report-2025-Vendor-Evaluation-Emphasizes-Data-Integration-Analytics-and-Patient-Centric-Approaches.html
- https://www.ziprecruiter.com/Jobs/Optum-Life-Sciences
- https://www.marketsandmarkets.com/ResearchInsight/real-world-evidence-solution-market.asp
- https://straitsresearch.com/report/real-world-evidence-solutions-market
- https://www.optumlabs.com/spotlights/optumlabs-spotlights/real-world-evidence.html